Full Text Journal Articles by
Author Martina Schmittnaegel

Advertisement

Find full text journal articles








Efficacy of CD40 agonists is mediated by distinct cDC subsets and subverted by suppressive macrophages.

Aleksandar Murgaski, Máté Kiss, Helena Van Damme, Daliya Kancheva, Isaure Vanmeerbeek, Jiri Keirsse, Eva Hadadi, Jan Brughmans, Sana M Arnouk, Ahmed E I Hamouda, Ayla Debraekeleer, Victor Bosteels, Yvon Elkrim, Louis Boon, Sabine Hoves, Niels Vandamme, Sofie Deschoemaeker, Sophie Janssens, Abhishek D Garg, Greetje Vande Velde, Martina Schmittnaegel, Carola H Ries, Damya Laoui,

Agonistic αCD40 therapy has been shown to inhibit cancer progression in only a fraction of patients. Understanding the cancer cell-intrinsic and microenvironmental determinants of αCD40 therapy response is therefore crucial to identify responsive patient populations and design efficient combinatorial treatments. Here, we show that the therapeutic efficacy of αCD40 in ... Read more >>

Cancer Res (Cancer research)
[2022, :CAN-22-0094]

Cited: 0 times

View full text PDF listing >>



Overcoming microenvironmental resistance to PD-1 blockade in genetically engineered lung cancer models.

Amaia Martinez-Usatorre, Ece Kadioglu, Gael Boivin, Chiara Cianciaruso, Alan Guichard, Bruno Torchia, Nadine Zangger, Sina Nassiri, Ioanna Keklikoglou, Martina Schmittnaegel, Carola H Ries, Etienne Meylan, Michele De Palma,

Immune checkpoint blockade (ICB) with PD-1 or PD-L1 antibodies has been approved for the treatment of non-small cell lung cancer (NSCLC). However, only a minority of patients respond, and sustained remissions are rare. Both chemotherapy and antiangiogenic drugs may improve the efficacy of ICB in mouse tumor models and patients ... Read more >>

Sci Transl Med (Science translational medicine)
[2021, 13(606):eabd1616]

Cited: 6 times

View full text PDF listing >>





Advertisement


Disclaimer

0.5386 s